Abstract: A system makes predictions using a machine learning model combined with a knowledge model. The system provides input data to a knowledge model and a machine learning based model. The machine learning based model is trained to make predictions based on input data. The system provides the outputs of the machine learning based model and the knowledge model to an ensemble model configured to combine results of the knowledge model and the machine learning based model. The system can be used for several applications. For example, the system may classify an input text based on a hierarchy of categories. The system may perform fault detection in time series data by identifying an anomaly data point and predicting whether the anomaly data point is a fault.

Abstract: A system makes predictions using a machine learning model combined with a knowledge model. The system provides input data to a knowledge model and a machine learning based model. The machine learning based model is trained to make predictions based on input data. The system provides the outputs of the machine learning based model and the knowledge model to an ensemble model configured to combine results of the knowledge model and the machine learning based model. The system can be used for several applications. For example, the system may classify an input text based on a hierarchy of categories. The system may perform fault detection in time series data by identifying an anomaly data point and predicting whether the anomaly data point is a fault.

Abstract: A system makes predictions using a machine learning model combined with a knowledge model. The system provides input data to a knowledge model and a machine learning based model. The machine learning based model is trained to make predictions based on input data. The system provides the outputs of the machine learning based model and the knowledge model to an ensemble model configured to combine results of the knowledge model and the machine learning based model. The system can be used for several applications. For example, the system may classify an input text based on a hierarchy of categories. The system may perform fault detection in time series data by identifying an anomaly data point and predicting whether the anomaly data point is a fault.

Abstract: An anomaly detection method for detecting an anomaly in an in-vehicle network of an in-vehicle network system including a plurality of electronic control units that transmit and receive messages via the network includes: generating image data of a reception interval between a plurality of messages included in a message sequence in a predetermined period out of a message sequence received from the in-vehicle network, or image data of a transition of a sensor value of the plurality of messages; classifying the image data using a trained CNN according to whether an attack message has been inserted in the predetermined period; and when the attack message has been inserted in the predetermined period, outputting a detection result indicating that an insertion attack which is an insertion of the attack message has been made in the predetermined period.

Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

Abstract: Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided.

Abstract: Embolic implants, methods of manufacture and delivery are disclosed. The subject implants are especially suitable for use is stent-caged aneurysm treatment.

Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

Abstract: Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided.

Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

Abstract: Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided.

Abstract: Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided.

Abstract: The subjected devices include a stent, a graft and a means for attaching the graft to the stent. One or more members are received in a permanent or temporary receptacle within the stent attach the graft to the stent. In one variation, an interference fit is employed; in another, the graft is bonded to a stent-captured member(s).

Abstract: Embolic implants, delivery systems and methods of manufacture and delivery are disclosed. The devices can be used for aneurysm treatment and/or parent vessel occlusion. Implant designs offer low profile compressibility for delivery to neurovasculature, while maintaining other necessary features such as density for occlusion purposes and desirable radial strength characteristics.

Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

Abstract: Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided.

Abstract: Methods and compounds for production of cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV are provided.